Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (June 22nd Preview)
-
FDA accelerates rare-disease gene therapy reconsideration for Hunter syndrome
Regulators reversed course again on Regenxbio’s childhood gene therapy for Hunter syndrome, setting up a new resubmission for RGX-121. Regenxbio said FDA staff now consider the company’s existing NAVSUNLI clinical data sufficient for an accelerated approval pathway, removing the need for additional patient enrollment or new studies. The latest pivot follows Regenxbio’s February rejection and subsequent appeal activity, including a request for a Type A meeting to review longer-term biomarker and clinical data. Regenxbio said it plans to resubmit in the third quarter after the July meeting, with FDA reviewing the filing on an expedited basis. Regenxbio said the FDA had previously flagged “uncertainty” around eligibility criteria and concerns about the comparability of external controls versus trial participants. Under the new position, the agency acknowledged the existing data support consideration, and labeling discussions are expected to begin shortly after resubmission. The move is the most recent example of changing regulatory stances for rare-disease therapies under new FDA leadership—important for gene therapy developers that rely on surrogate endpoints, external controls, and accelerated approval pathways.
-
AbbVie bets on long-acting immunology with $10.9B Apogee acquisition
AbbVie agreed to buy Apogee Therapeutics in a deal valued at $10.9 billion in cash, positioning the pharma company to expand in long-acting immune therapies. The transaction gives AbbVie Apogee’s lead IL-13 program, zumilokibart (an anti–IL-13 therapy) and additional immunology candidates, including development-stage assets aimed at inflammatory diseases. Zumilokibart is designed for infrequent dosing—AbbVie highlighted the potential for administration only a few times per year after initial treatment—targeting multiple indications in atopic dermatitis and asthma. Analysts and investors will focus on whether the long-acting profile can differentiate it against established biologics and small molecules in immune-mediated disease. The acquisition underscores a continued shift toward late-stage immunology platforms where dosing convenience and differentiated mechanisms are increasingly central to market share. For Apogee, the deal provides scale to fund pivotal trials and commercialization planning. For AbbVie, the purchase expands its immunology portfolio with an IL-13 approach that overlaps with competitive arenas across inflammatory bowel disease and dermatology franchises.
-
Merck’s anti–TL1A antibody logs Phase 3 win in ulcerative colitis
Merck said its anti-TL1A antibody tulisokibart (developed from the Prometheus Biosciences acquisition) achieved a positive Phase 3 result in ulcerative colitis. In the ATLAS-UC induction-only study of patients with moderately to severely active disease, Merck reported benefit versus placebo on clinical remission at week 12 using the Modified Mayo Score, and it said no safety concerns emerged. Merck indicated it will share detailed results with regulators and at an upcoming scientific meeting, alongside data from an ongoing induction and maintenance study. The company framed the result as the first clinical-remission positive outcome at 12 weeks for the anti-TL1A approach in this patient population. The update adds momentum to Merck’s immunology strategy in a crowded UC market where IL-23 inhibitors, JAK inhibitors, and integrin-based therapies compete for switching and line-of-therapy decisions. Merck is also running additional trials across Crohn’s disease and other immune-mediated indications. Industry focus will now center on whether the drug demonstrates differentiation beyond induction—especially around durability, endoscopic improvement, and biomarker-defined responses as more data mature.
-
Definium’s single-dose LSD therapy clears Phase 3 bar in major depression
Definium reported that its single-dose LSD-inspired therapy DT120 produced clinically meaningful improvement in a Phase 3 trial for major depressive disorder. Six weeks after dosing, patients treated with DT120 saw a 13.3-point drop on the MADRS depression scale versus 5.2 points with placebo. At 12 weeks, the antidepressant effect narrowed but remained largely sustained, with an 11.0-point drop from baseline for DT120 compared with 3.6 points for placebo. Definium said the results bring the candidate closer to potential regulatory discussions. Investors and psychiatrists will now scrutinize whether the effect profile supports differentiation versus other late-stage approaches, and how durability plays out in longer follow-up. Trial safety, functional endpoints, and comparisons across subgroups are likely to shape the next-stage narrative. The Phase 3 readout also adds momentum to the resurgence of psychedelic-assisted development strategies that target rapid symptom change.
-
FDA and pediatric trial acceleration plan
The U.S. Department of Health and Human Services outlined efforts designed to speed up early-stage clinical trials by 6 to 12 months, as the biotech community convenes for BIO 2026 in San Diego. The plan aims to help regain time in early development and encourage U.S.-based trial starts. The announcement ties into the broader push for faster Investigational New Drug (IND) activity through changes to existing pathways and potential permanent process reforms. The goal is to reduce friction in trial initiation, thereby narrowing timelines between IND clearance and active enrollment. For developers, the primary question is how the agencies will operationalize the timeline reductions across sponsors, IRBs, and trial execution. Even modest process acceleration can affect capital allocation and the probability of hitting pivotal program milestones. The policy move also signals heightened attention to global competition in early clinical development capacity.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.